The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
Author(s) -
Nils-Henning Neß,
Rocco Haase,
Raimar Kern,
Dirk Schriefer,
Benjamin Ettle,
Christian Cornelissen,
Katja Akguen,
Tjalf Ziemssen
Publication year - 2020
Publication title -
journal of medical internet research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.446
H-Index - 142
eISSN - 1439-4456
pISSN - 1438-8871
DOI - 10.2196/17921
Subject(s) - intraclass correlation , guttman scale , discriminant validity , construct validity , convergent validity , reliability (semiconductor) , medicine , observational study , criterion validity , psychology , physical therapy , clinical psychology , psychometrics , developmental psychology , pathology , power (physics) , physics , quantum mechanics , internal consistency
Background Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. Objective The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. Methods We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. Results In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability ( r =0.411, P <.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. Conclusions The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom